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being associated with a rise in the average of laboratory tests and more hospitaliza-
tions. Direct cost for patients ranged from 6,066.8€ (> 500 cells/mL) to 7,654.3€ (< 200 
cells/mL). ConClusions: The total direct cost of HIV-infection seems to increase 
with advanced disease. Considering the reduction of available resources, especially 
in a country such as Greece, where austerity measures take place, effective disease 
management represents a major challenge, and the improvement of health services 
provided to HIV patients is more than compelling.
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objeCtives: Seasonal influenza occurs in annual epidemics usually peaking dur-
ing winter. The seasonal influenza virus can cause mild to severe illness and poses 
a burden for patients of all age groups. The objective of this study is to assess the 
disease burden and vaccination-rates based on claims data in different age groups 
for the influenza season 2012/2013 in Germany. Methods: We conducted a ret-
rospective claims data analysis using the Health Risk Institute research database, 
containing anonymized data of 3,953,260 individuals (appr. 4.9% of the German 
population). The study period comprised 1 October 2012 to 30 June 2013, patients 
were identified based on the ICD-10-GM codes for influenza. Vaccine-rates were cal-
culated by identifying documented vaccinations. The disease burden was assessed 
based on occurring secondary diseases and health services utilization in the inpa-
tient and outpatient sector. The relative frequency of the most common concomi-
tant diseases (otitis media, pneumonia) was evaluated and compared to individuals 
not infected with influenza. Results were compared and validated against existing 
evidence. Results: We observed 65,826 patients with a documented influenza dur-
ing the influenza season 2012/2013. The occurrence of otitis media and pneumonia 
was higher in all age groups compared to the non-influenza-infected population and 
especially high in children. A total of 848 influenza-related hospitalizations were 
identified with a mean duration of 6 days, amounting to € 4,945,686 and 8,532 days 
of inpatient care. Overall, 65% of these hospitalizations were caused by influenza 
(principal diagnosis), and even over 80% for patients aged 2-17 years. Moreover, total 
outpatient costs amounted to € 14,947,976. Finally, vaccination-rates were below 4% 
for children and 37% for patients aged > 60. ConClusions: Seasonal influenza 
can cause severe outcomes leading to hospitalizations and excess costs. Especially 
influenza-infected children are affected by concomitant diseases resulting in a 
higher disease burden. Furthermore, documented vaccination-rates are quite low.
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objeCtives: The hepatitis C virus (HCV) induces several pathological conditions 
worldwide with a substantial medical and economic burden. The objective of this 
study is to estimate the average annual cost incurred by the National Health Service 
(NHS) as well as society due to HCV in Italy. Methods: A probabilistic incidence-
based cost of illness model was developed to estimate an aggregate measure of the 
economic burden associated with HCV-related diseases either in terms of direct or 
indirect costs (impact of absenteeism computed according to the human capital 
method). A systematic literature review was carried out to reveal both epidemiologi-
cal and economic data. Furthermore, a one-way probabilistic sensitivity analysis 
with 5,000 Monte Carlo simulations was performed, in order to test the robustness 
of results and define the proper 95%CI. Results: Overall, the total economic burden 
associated with HCV-related diseases was estimated in € 1,05 (95%CI: € 0,61-€ 1,61) 
billion. A percentage equal to 61,4% were associated with indirect costs (95% CI: 
€ 0,37-€ 0,99 billion) and 38,6% with direct costs (95% CI: € 0,23-€ 0,63 billion). For 
chronic hepatitis C, cirrhosis, hepatocellular carcinoma (HCC), liver transplantation 
and death from causes related to HCV was estimated an average annual economic 
burden amounting to € 0,26 (95%CI: € 0,14-€ 0,41), € 0,55 (95%CI: € 0,30-€ 0,87), € 
0,051 (95%CI: € 0,0001-€ 0,25) € 0,05 (95%CI: € 0,03-€ 0,08) and € 0,15 (95%CI: € 0,06-€ 
0,27) billion, respectively. ConClusions: Italy is one of the European countries 
with the highest number of people with chronic HCV infection, the leading cause 
of cirrhosis, HCC and liver-related death. HCV-related diseases causes a significant 
cost for Italian NHS, especially for each case of liver transplantation. These highly 
debilitating and life-threatening complications generate a rather large amount of 
indirect costs for the Italian society as well.
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objeCtives: During the influenza epidemic period (2009-2010) 17 % of Ukrainian 
population were sick. The aim was to assess the dynamics of incidence rates. We 
analyzed the costs of treating influenza and acute respiratory infections (ARI) in the 
four stages of medical care: 1 - primary care (PCP), 2-out-patient, 3-hospital, 4-inten-
sive care unit during the period 2009-2010 (pandemic) vs 2010-2011. Methods: We 
used the statistic data of the MoH of Ukraine, the incidence of influenza and ARI, and 
method “cost of illness” per 1 patient. Results: In 2009-2010 influenza rate and ARI 
was 472,6 per 100000 population. The vaccination coverage was 239,104 people, that 
representing 0.518% of the total population. In 2010-2011 the ifluenza rate and ARI was 
420.9 per 100000, respectively. The vaccination coverage was 602911 persons during 
2010-2011 years, that’s 1,312% of the total population. We obtained the following costs 
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objeCtives: Examine the economic burden and health care utilizations of the 
chronic hepatitis C (CHC) in the U. S. veteran population. Methods: A retrospective 
database analysis was performed using the U. S. Veterans Health Administration 
Medical SAS datasets (01OCT2007-30SEP2012). Patients diagnosed with CHC 
(International Classification of Disease 9thRevision Clinical Modification [ICD-9-CM] 
codes 070.44, 070.54, 070.70, 070.71) were identified, and the first diagnosis date 
served as the index date. A comparator group was created by identifying patients 
without a CHC diagnosis but of the same age, region, gender and index year, and 
matched according to baseline Charlson Comorbidity Index scores. The index date 
for the comparator group was randomly chosen to reduce selection bias. A 1-year 
continuous enrollment period pre- and post-index date was required for both 
groups. One-to-one propensity score matching (PSM) was used to compare health 
care costs and utilizations during the follow-up period between the cohorts, adjust-
ing for baseline demographic and clinical characteristics. Results: Eligible patients 
(N= 87,837) were identified for the CHC and comparison cohorts. After applying 
1:1 PSM, a total of 69,809 patients were matched from each group and baseline 
characteristics were well-balanced. CHC patients were more likely to be hospital-
ized (33.47% vs. 2.42%, p< 0.0001) and had more emergency room (ER) (28.55% vs. 
6.68%, p< 0.0001), physician office (98.65% vs. 53.56%, p< 0.0001), outpatient (98.81% 
vs. 54.46%, p< 0.0001) and pharmacy visits (88.73% vs. 57.18%, p< 0.0001), resulting 
in higher health care costs for inpatient ($11,303 vs. $691, p< 0.0001), ER ($345 vs. 
$60, p< 0.0001), outpatient ($5,540 vs. $1,382, p< 0.0001), physician office ($4,956 
vs. $1,230, p< 0.0001), pharmacy ($947 vs. $433, p< 0.0001) and total costs ($17,789 vs. 
$2,506, p< 0.0001) for CHC patients, relative to comparison patients. ConClusions: 
U.S. veterans diagnosed with CHC were more likely to have higher health care 
resource utilization and were associated with a higher economic burden compared 
to matched controls.
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objeCtives: To accurately estimate hospitalization costs of Community-Acquired 
Pneumonia (CAP) in elderly in the Netherlands. Methods: This observational 
study was part of the CAPiTA-trial [1] and was conducted in 54 hospitals in the 
Netherlands between October 2008 and August 2013. CAPiTA participants with a sus-
picion of CAP were included. CAP was diagnosed on clinical and radiographic criteria 
according to the CAPiTA protocol. A re-admission within 30 days was considered as 
one episode. Data on health care use were collected prospectively using clinical files. 
Hospitalization costs were stratified by age-group (65-74, 75-84 and ≥ 85) and risk cat-
egories based on comorbidities (high (i.e. immunocompromised patients), medium 
(i.e. presence of other chronic conditions) and low). Costs are presented for the year 
2012. Results: 3,141 suspected CAP episodes were included. 1,835 confirmed CAP 
episodes (58.4%) were reported of which 124 cases were readmissions (6.8%). The 
first admission resulted in an overall mean length of hospital stay of 10.94 (SD ±9) 
days, in-hospital mortality rate of 10.7%, and average costs of € 7,219 (95% CI [€ 6,653, 
€ 7,833]). General ward nursing cost accounted for 67.4% of all costs and ICU nursing 
for 27.8%. For the age-categories 65-74, 75-84 and ≥ 85 mean length of hospital stay 
was respectively 11.23,10.86 and 10.56 days (p= 0.534), fatality rate was 7,8%, 10,6%, 
and 15,5% (p= 0,001) and mean hospitalization costs were € 7,985, € 7,240, € 5,774 
(p= 0.041). When stratified by risk, the highest risk group showed the lowest mean 
costs (€ 6,551, p= 0.019) and the highest mortality (21%). ConClusions: Health care 
costs decline with age and risk severity. The eldest age group experienced shorter 
ICU admissions and high mortality. Patients with medium and high risk for devel-
oping CAP showed a higher mortality rate and lower costs. 1. Hak, E., et al., Neth J 
Med, 2008.66 (9): p. 378-83.
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objeCtives: HIV-infection nowadays represents a chronic disease of high com-
plexity affecting populations worldwide. Highly active antiretroviral therapy, where 
available, has resulted in prolonged life expectancy and increased quality of life, 
through an ever-increasing cost of HIV-infection. The present study aimed at esti-
mating the health resources consumed by HIV-infected patients and their respective 
direct costs, on an annual basis, in Greece. Methods: A retrospective study was 
performed in order to collect data from the medical records of 447 HIV-infected 
patients, followed in an Infectious Diseases Unit in Athens. The survey included all 
services and antiretroviral treatment that patients received in one year as well as 
their demographic data. The subjects of the study were stratified in three health 
states according to the CD4+ counts, as defined by the CDC classification system 
for HIV infection. The cost analysis evaluating the direct cost of HIV-infection was 
undertaken from a third-party payer perspective. Results: The annual direct cost 
was calculated at 6,860.3€ /patient, the largest part being attributed to antiretroviral 
therapy (5,741.8€ , p= NS). The respective cost for providing health care services was 
estimated at 1,118.5€ , with laboratory tests representing 13.5% of total cost (P< 0.05), 
while hospitalization and outpatient visits accounted for 2.3% (p< 0.05) and 0.5% 
(p= NS) respectively. Overall, direct cost/patient increased for lower CD4+ counts, 
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tocellular carcinoma (HCC) rates and health care costs of treated and untreated 
patients were compared using propensity score matching. Baseline demographic 
and clinical factors were controlled in the models. Subgroup analysis was con-
ducted for patient groups with and without a cirrhosis diagnosis. Results: A total 
12,990 patients, of whom 2,467 were diagnosed with cirrhosis, were included in the 
study. 12.2% of the overall population was treated for HCV. Treated patients were 
younger, less likely to reside in Central or Eastern Anatolia and less likely to have 
comorbidities. After adjusting for baseline demographic and clinical factors, mor-
tality rates (2.27% vs. 5.31%, p< 0.001) and HCC rates (0.69% vs. 1.96%, p< 0.001) were 
significantly lower for treated HCV patients. The differences were more significant 
among cirrhosis patients. Total risk-adjusted annual costs were significantly higher 
for treated patients (€ 6,172 vs. € 1,680, p< 0.001), mainly due to higher pharmaceutical 
costs (€ 4,918 vs. € 583, p< 0.001). ConClusions: HCV treatment, although costly, 
significantly reduces mortality and HCC rates in Turkey.
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objeCtives: Health care workers (HCW) are at particular risk of acquiring pertussis 
and transmitting the infection to high-risk susceptible patients and colleagues. In 
this paper, the Return On Investment (ROI) of preventively vaccinating HCW against 
pertussis to prevent nosocomial pertussis outbreaks is estimated using a hospi-
tal ward perspective, presuming an outbreak occurs once in 10 years. Methods: 
Data on the pertussis outbreak on the neonatology ward in 2004 in the Academic 
Medical Center Amsterdam (The Netherlands) was used to calculate control costs 
and other outbreak related costs. The study population was: neonatology ward 
staff members (n= 133), parents (n= 40), neonates (n= 20), and newborns transferred 
to other hospitals (n= 23). ROI is presented as the amount of Euros saved in avert-
ing outbreaks by investing one Euro in preventively vaccinating HCW. Sensitivity 
analysis was performed to study the robustness of the ROI. Results are presented at 
2012 price level. Results: Total nosocomial pertussis outbreak costs were € 48,682. 
Direct control costs (i.e. Antibiotic therapy, laboratory investigation and outbreak 
management control) were € 11,464. Other outbreak related costs (i.e. sick leave of 
HCW; restrictions on the neonatology ward, savings due to reduced working force) 
accounted for € 37,218. Vaccination costs would be € 12,208. The ROI of preventively 
vaccinating HCW against pertussis was 1: 4, meaning 4 Euros could be saved by every 
Euro invested in vaccinating HCW to avert outbreaks. ROI was sensitive to a lower 
vaccine price, considering direct control costs only, average length of stay neonates 
on the neonatology ward, length of patient uptake restrictions, assuming no reduced 
work force due to ward closer and presuming more than one outbreak to occur in 10 
years’ time. ConClusions: From a hospital ward perspective, preventive vaccina-
tion of HCW against pertussis to prevent nosocomial pertussis outbreaks results in 
a positive ROI, presuming an outbreak occurs once in 10 years.
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objeCtives: Methicillin-resistant Staphylococcus aureus (MRSA) infections cause 
heavy financial burden on health care systems worldwide. Hospital admission 
screening has been proven as an effective method to prevent nosocomial MRSA 
transmission. However, previous cost studies mostly refer to screening regimes 
for a limited area of hospitals (e. g. ICU) a limited period of intervention (< 1 year) 
or rely on culture tests only. The aim of this study was to determine the long-term 
costs and benefits of a targeted hospital wide PCR-based admission screening for 
MRSA. Methods: We performed a six-year (2008-2013) retrospective analysis of 
the step-wise implementation of a hospital-wide PCR-based admission screening 
of defined risk patients for MRSA in a 926-bed tertiary hospital. Screening costs 
includes PCR-screening (screening rate 10.7-14.7%) and cultural test confirmation in 
case of a positive test result as well as hygienic measures for pre-emptive isolation 
of all screened patients. The benefit is calculated based on prevented nosocomial 
MRSA infections (reference year 2007), assuming that 8,673 Euros will be saved per 
case. Results: During the study period, prevented nosocomial MRSA-infections 
resulted in total cost savings of at least 1,329,714 Euros. This is opposed by costs for 
targeted PCR-screening of 670,234 Euros and 441,448 Euros for pre-emptive isolation 
measures. The save/cost-ratio was calculated with 1.196, the save-cost-difference 
with 36,339 Euros per year. ConClusions: Our study shows the advantage of a 
PCR-based admission screening by a positive cost-saving-difference. Nevertheless, 
this advantage depends on cost drivers included in the analysis and the definition 
of risk factors which determine the proportion of patients to be screened. For a true 
image, the opportunity costs for reimbursement losses due to blocked beds during 
isolation as well as additional savings for prevented nosocomial MRSA-colonizations 
have to be taken into consideration.
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per 1 patient: 1. Flu patients at PCP, average number of visits/patient in 2009-2010 were 
7753635 sick persons, 2010-2011– 7502008 sick persons. Total cost of the disease was 
80,39 UAH per 1 patient (1 Euro= 10 UAH on 01.06.2011). 2. Flu patients in out-patient 
clinic during 2009/10 were registered 1962839 request for medical assistance about 
influenza and ARI. In the season, 2010/11 - registered 1785102 who needed medical 
care for influenza and ARI, total cost was 202,07 UAH. 3. Flu patients in hospital dur-
ing 2009-2010 were hospitalized 47108 persons. Total cost of the disease was 728,85 
UAH. 4. Flu patients in intensive care unit – the total cost of the disease was 2543,08 
UAH. ConClusions: Established the high costs for the hospitalization were 2543,08 
UAH per 1 patient comparіng with 80,39 UAH at PCP. Govermental program to prevent 
influenza by vaccination can to reduce the cost of flu treating.
PIN47
Cost of CIrrHosIs amoNG PatIeNts dIaGNosed wItH HePatItIs C vIrus 
IN turkey
Baser O.1, Kariburyo M.F.2, Baser E.3, Altinbas A.4
1STATinMED Research and The University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA, 3STATinMED Research and Gazi University, Ankara, Turkey, 
4Diskapi Yildirim Beyazit Education and Research Hospital, Gastroenterology Clinic, Ankara, 
Turkey
objeCtives: 3-11% of patients diagnosed with chronic hepatitis C virus (HCV) 
infection will develop liver cirrhosis within 20-30 years, with an associated risk 
of liver failure and hepatocellular carcinoma (HCC). Mortality, HCC rates and costs 
of HCV patients were compared among cirrhosis and non-cirrhosis patients in 
Turkey. Methods: Using the Turkish National Health Insurance Database (2009-
2011), HCV patients were identified using International Classification of Disease, 
10th Revision, Clinical Modification codes. Propensity score matching (PSM) was 
applied to compare cirrhosis and non-cirrhosis cohorts. Baseline demographic and 
clinical factors were controlled in the models. Results: A total of 12,990 patients, 
including 2,467 diagnosed with cirrhosis, were included in the study. 12.2% of the 
overall population was treated. Cirrhosis patients were older (61.56 vs. 51.10 years, 
p< 0.001), more likely to reside in the Black Sea region (26.96% vs. 23.77%, p< 0.001) 
and had Elixhauser comorbidity index scores ≥ 2 (89.30% vs. 66.06%, p< 0.001). In par-
ticular, these patients were more likely to be diagnosed with comorbidities such as 
biliary disease, hepatitis B, congestive heart disease, respiratory disease, hyperten-
sion and diabetes. After all baseline differences were controlled, patients diagnosed 
with cirrhosis showed higher mortality (23.87% vs. 5.14%, p< 0.001) and HCC rates 
(8.10% vs. 1.05%, p< 0.001). Disease-related costs were significantly higher (€ 3,254 
vs. € 1,996; p< 0.001). ConClusions: Cirrhosis mortality, HCC rates and costs of 
cirrhosis among HCV patients are significantly higher in Turkey.
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objeCtives: Although prevention accounts for a minor part of the health care 
spending (< 3%) in Europe, preventative programs and particularly vaccinations 
are most vulnerable to budget cuts and restrictions as their benefits may not be 
immediately identifiable. This pan-European project aims at evaluating the lifelong 
costs per individual vaccinated in full compliance with the national recommenda-
tions. French results are presented below. Methods: A calculation Excel model 
was developed and fed with the most recent French specific data: 2014 vaccination 
calendar from High Council of Public Health, life expectancy at birth from WHO, 
list prices from National health insurance database (NHI: AMELI). Reimbursement 
rates were applied to total costs to reflect NHI perspective. A 100% compliance 
rate was assumed. When several vaccines were available for a similar preventative 
indication, the list price of the product with the highest 2013 market share was 
considered. Lifelong vaccine costs were calculated for 4 categories of individuals: 
man/woman, without/with underlying conditions. For individuals with underlying 
conditions, the following specific recommendations were considered: Tuberculosis, 
Hepatitis B, Influenza, Hepatitis A, Pertussis, Pneumococcal diseases, Varicella. 
Three recommended vaccinations (Zoster, Rotavirus, Meningococcal B diseases) 
without official prices were not included. Results: In 2014, total lifelong vaccines 
costs ranged from € 524 (men without underlying conditions) to € 1379 (women 
with underlying conditions), covering 12 to 16 diseases respectively. Differences 
in costs are linked to gender specificities (life expectancy, Human Papillomavirus 
vaccination), or to recommendations specific to underlying conditions. Since only 
reimbursed vaccines are considered, most of vaccines costs are funded by the NHI 
(72% to 82%). ConClusions: These total costs of vaccines throughout life should 
be considered as maximal since in practice few people fully comply with all recom-
mendations of the National vaccination calendar. Policy makers shall appreciate 
that prevention through vaccination involves low levels of investment relative to 
its substantial benefits.
PIN49
eCoNomIC BurdeN aNd ComPlICatIoNs of HePatItIs C vIrus PatIeNts 
wItH aNd wItHout PeGINterferoN aNd rIBavIrIN treatmeNt IN turkey
Baser O.1, Kariburyo M.F.2, Altinbas A.3, Baser E.4
1STATinMED Research and The University of Michigan, Ann Arbor, MI, USA, 2STATinMED 
Research, Ann Arbor, MI, USA, 3Diskapi Yildirim Beyazit Education and Research Hospital, 
Gastroenterology Clinic, Ankara, Turkey, 4STATinMED Research and Gazi University, Ankara, 
Turkey
objeCtives: To compare health care outcomes between hepatitis c virus (HCV) 
patients who were prescribed pegylated interferon-alpha with or without ribavirin 
to those who were not prescribed these medications. Methods: Using the Turkish 
National Heath Insurance Database (2009-2011), HCV patients were identified using 
International Classification of Disease, 10th Revision, Clinical Modification codes. 
The first prescription date was designated as the index date. Mortality and hepa-
